the effect of existing and any new healthcare laws and regulations currently being considered or implemented in the U.S. and globally, including most-favored nation pricing measures, measures requiring the U.S. government in the future to negotiate the prices of certain drugs, and price reporting and other disclosure requirements, as well as the potential impacts of such requirements on physician prescribing practices and payor coverage;
All entries for: Alnylam Pharmaceuticals, Inc.
February 12, 2026
Alnylam Pharmaceuticals, Inc.
Neutral Outlook
Cambridge, MA
1,001-5,000 employees
Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties or a potential excise tax. The impact of the IRA on the pharmaceutical industry is significant and ongoing.
Disease Area: Cardiology, Metabolic Diseases, Neurological Diseases, Rare Disease
Drug Type: Biologic